{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,5]],"date-time":"2026-04-05T20:20:29Z","timestamp":1775420429427,"version":"3.50.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T00:00:00Z","timestamp":1675641600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T00:00:00Z","timestamp":1675641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"This work was partly financed by the Italian Ministry of Health and the Lombardia Region","award":["(Grant NET-2016-02364191 \u2013 EASY-NET)."],"award-info":[{"award-number":["(Grant NET-2016-02364191 \u2013 EASY-NET)."]}]},{"name":"This work was partly financed by the Italian Ministry of Health and the Lombardia Region","award":["(Grant NET-2016-02364191 \u2013 EASY-NET)."],"award-info":[{"award-number":["(Grant NET-2016-02364191 \u2013 EASY-NET)."]}]},{"name":"This work was partly financed by the Italian Ministry of Health and the Lombardia Region","award":["(Grant NET-2016-02364191 \u2013 EASY-NET)."],"award-info":[{"award-number":["(Grant NET-2016-02364191 \u2013 EASY-NET)."]}]},{"name":"This work was partly financed by the Italian Ministry of Health and the Lombardia Region","award":["(Grant NET-2016-02364191 \u2013 EASY-NET)."],"award-info":[{"award-number":["(Grant NET-2016-02364191 \u2013 EASY-NET)."]}]},{"name":"This work was partly financed by the Italian Ministry of Health and the Lombardia Region","award":["(Grant NET-2016-02364191 \u2013 EASY-NET)."],"award-info":[{"award-number":["(Grant NET-2016-02364191 \u2013 EASY-NET)."]}]},{"name":"This work was partly financed by the Italian Ministry of Health and the Lombardia Region","award":["(Grant NET-2016-02364191 \u2013 EASY-NET)."],"award-info":[{"award-number":["(Grant NET-2016-02364191 \u2013 EASY-NET)."]}]},{"name":"This work was partly financed by the Italian Ministry of Health and the Lombardia Region","award":["(Grant NET-2016-02364191 \u2013 EASY-NET)."],"award-info":[{"award-number":["(Grant NET-2016-02364191 \u2013 EASY-NET)."]}]},{"name":"This work was partly financed by the Italian Ministry of Health and the Lombardia Region","award":["(Grant NET-2016-02364191 \u2013 EASY-NET)."],"award-info":[{"award-number":["(Grant NET-2016-02364191 \u2013 EASY-NET)."]}]},{"name":"This work was partly financed by the Italian Ministry of Health and the Lombardia Region","award":["(Grant NET-2016-02364191 \u2013 EASY-NET)."],"award-info":[{"award-number":["(Grant NET-2016-02364191 \u2013 EASY-NET)."]}]},{"name":"This work was partly financed by the Italian Ministry of Health and the Lombardia Region","award":["(Grant NET-2016-02364191 \u2013 EASY-NET)."],"award-info":[{"award-number":["(Grant NET-2016-02364191 \u2013 EASY-NET)."]}]},{"name":"This work was partly financed by the Italian Ministry of Health and the Lombardia Region","award":["(Grant NET-2016-02364191 \u2013 EASY-NET)."],"award-info":[{"award-number":["(Grant NET-2016-02364191 \u2013 EASY-NET)."]}]},{"name":"This work was partly financed by the Italian Ministry of Health and the Lombardia Region","award":["(Grant NET-2016-02364191 \u2013 EASY-NET)."],"award-info":[{"award-number":["(Grant NET-2016-02364191 \u2013 EASY-NET)."]}]},{"name":"This work was partly financed by the Italian Ministry of Health and the Lombardia Region","award":["(Grant NET-2016-02364191 \u2013 EASY-NET)."],"award-info":[{"award-number":["(Grant NET-2016-02364191 \u2013 EASY-NET)."]}]},{"name":"This work was partly financed by the Italian Ministry of Health and the Lombardia Region","award":["(Grant NET-2016-02364191 \u2013 EASY-NET)."],"award-info":[{"award-number":["(Grant NET-2016-02364191 \u2013 EASY-NET)."]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Glucagon-like peptide-1 receptor agonists (GLP-1 RA) and sodium glucose cotransporter-2 inhibitors (SGLT-2i) demonstrated cardiovascular and renal protection. Whether their benefits occur also during hospitalization for acute myocardial infarction (AMI) in patients with diabetes mellitus (DM) is not known. We evaluated in-hospital outcomes of patients hospitalized with AMI according to their chronic use of GLP-1 RA and\/or SGLT-2i.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Using the health administrative databases of Lombardy, patients hospitalized with AMI from 2010 to 2019 were included. They were stratified according to DM status, then grouped into three cohorts using a propensity score matching: non-DM patients; DM patients treated with GLP-1 RA and\/or SGLT-2i; DM patients not treated with GLP-1 RA\/SGLT-2i. The primary endpoint of the study was the composite of in-hospital mortality, acute heart failure, and acute kidney injury requiring renal replacement therapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We identified 146,798 patients hospitalized with AMI (mean age 71\u2009\u00b1\u200913\u00a0years, 34% females, 47% STEMI; 26% with DM). After matching, 3,090 AMI patients (1030 in each group) were included in the analysis. Overall, the primary endpoint rate was 16% (n\u2009=\u2009502) and progressively increased from non-DM patients to DM patients treated with and without GLP-1 RA\/SGLT-2i (13%, 16%, and 20%, respectively; P\u2009&lt;\u20090.0001). Compared with non-DM patients, DM patients with GLP-1 RA\/SGLT-2i had a 30% higher risk of the primary endpoint, while those not treated with GLP-1 RA\/SGLT-2i had a 60% higher risk (P\u2009&lt;\u20090.0001).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Chronic therapy with GLP-1 RA and\/or SGLT-2i has a favorable impact on the clinical outcome of DM patients hospitalized with AMI.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12933-023-01758-y","type":"journal-article","created":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T18:03:11Z","timestamp":1675706591000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Impact of chronic GLP-1 RA and SGLT-2I therapy on in-hospital outcome of diabetic patients with acute myocardial infarction"],"prefix":"10.1186","volume":"22","author":[{"given":"Filippo","family":"Trombara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Cosentino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Bonomi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Ludergnani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Poggio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigia","family":"Gionti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Baviera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierluca","family":"Colacioppo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Carla","family":"Roncaglioni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivia","family":"Leoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Bortolan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piergiuseppe","family":"Agostoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Genovese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giancarlo","family":"Marenzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,2,6]]},"reference":[{"issue":"2","key":"1758_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1177\/2047487319881021","volume":"26","author":"E Standl","year":"2019","unstructured":"Standl E, Khunti K, Hansen TB, Schnell O. The global epidemics of diabetes in the 21st century: current situation and perspectives. Eur J Prev Cardiol. 2019;26(2):7\u201314.","journal-title":"Eur J Prev Cardiol"},{"key":"1758_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4061\/2011\/145615","volume":"2011","author":"B Ovbiagele","year":"2011","unstructured":"Ovbiagele B, Markovic D, Fonarow GC. Recent US patterns and predictors of prevalent diabetes among acute myocardial infarction patients. Cardiol Res Pract. 2011;2011:1\u20138.","journal-title":"Cardiol Res Pract"},{"key":"1758_CR3","doi-asserted-by":"publisher","first-page":"847","DOI":"10.2337\/dc17-1732","volume":"41","author":"G Marenzi","year":"2018","unstructured":"Marenzi G, Cosentino N, Milazzo V, et al. Prognostic value of the acute-to-chronic glycemic ratio at admission in acute myocardial infarction: a prospective study. Diabetes Care. 2018;41:847\u201353.","journal-title":"Diabetes Care"},{"key":"1758_CR4","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.114.001090","author":"B Ahmed","year":"2014","unstructured":"Ahmed B, Davis HT, Laskey WK. In-hospital mortality among patients with type 2 diabetes mellitus and acute myocardial infarction: results from the national inpatient sample, 2000\u20132010. J Am Heart Assoc. 2014. https:\/\/doi.org\/10.1161\/JAHA.114.001090.","journal-title":"J Am Heart Assoc"},{"key":"1758_CR5","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.jacc.2006.09.045","volume":"49","author":"C Berry","year":"2007","unstructured":"Berry C, Tardif J-C, Bourassa MG. Coronary heart disease in patients with diabetes. J Am Coll Cardiol. 2007;49:643\u201356.","journal-title":"J Am Coll Cardiol"},{"key":"1758_CR6","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ijcard.2020.08.021","volume":"323","author":"S Burgess","year":"2021","unstructured":"Burgess S, Juergens CP, Yang W, et al. Cardiac mortality, diabetes mellitus, and multivessel disease in ST elevation myocardial infarction. Int J Cardiol. 2021;323:13\u20138.","journal-title":"Int J Cardiol"},{"key":"1758_CR7","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/5584_2020_481","volume":"1307","author":"V Milazzo","year":"2021","unstructured":"Milazzo V, Cosentino N, Genovese S, et al. Diabetes mellitus and acute myocardial infarction: impact on short and long-term mortality. Adv Exp Med Biol. 2021;1307:153\u201369.","journal-title":"Adv Exp Med Biol"},{"key":"1758_CR8","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.2337\/dc19-0047","volume":"42","author":"G Marenzi","year":"2019","unstructured":"Marenzi G, Cosentino N, Genovese S, et al. Reduced cardio-renal function accounts for most of the in-hospital morbidity and mortality risk among patients with type 2 diabetes undergoing primary percutaneous coronary intervention for st-segment elevation myocardial infarction. Diabetes Care. 2019;42:1305\u201311.","journal-title":"Diabetes Care"},{"key":"1758_CR9","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","volume":"7","author":"SL Kristensen","year":"2019","unstructured":"Kristensen SL, R\u00f8rth R, Jhund PS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019;7:776\u201385.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1758_CR10","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1161\/CIRCULATIONAHA.118.038868","volume":"139","author":"TA Zelniker","year":"2019","unstructured":"Zelniker TA, Wiviott SD, Raz I, et al. Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus. Circulation. 2019;139:2022\u201331.","journal-title":"Circulation"},{"key":"1758_CR11","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394:121\u201330.","journal-title":"Lancet"},{"key":"1758_CR12","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1161\/CIRCULATIONAHA.118.035901","volume":"138","author":"BL Neuen","year":"2018","unstructured":"Neuen BL, Ohkuma T, Neal B, et al. Cardiovascular and renal outcomes with canagliflozin according to baseline kidney function. Circulation. 2018;138:1537\u201350.","journal-title":"Circulation"},{"key":"1758_CR13","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1161\/CIRCULATIONAHA.117.028268","volume":"137","author":"C Wanner","year":"2018","unstructured":"Wanner C, Lachin JM, Inzucchi SE, et al. Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease. Circulation. 2018;137:119\u201329.","journal-title":"Circulation"},{"key":"1758_CR14","doi-asserted-by":"publisher","first-page":"975","DOI":"10.2337\/db08-1193","volume":"58","author":"MH Noyan-Ashraf","year":"2009","unstructured":"Noyan-Ashraf MH, Momen MA, et al. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes. 2009;58:975\u201383.","journal-title":"Diabetes"},{"key":"1758_CR15","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1093\/eurheartj\/ehr309","volume":"33","author":"J L\u00f8nborg","year":"2012","unstructured":"L\u00f8nborg J, Vejlstrup N, Kelb\u00e6k H, et al. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur Heart J. 2012;33:1491\u20139.","journal-title":"Eur Heart J"},{"key":"1758_CR16","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.3389\/fphys.2017.01077","volume":"8","author":"I Andreadou","year":"2017","unstructured":"Andreadou I, Efentakis P, Balafas E, et al. Empagliflozin limits myocardial infarction in vivo and cell death in vitro: role of STAT3, mitochondria, and redox aspects. Front Physiol. 2017;8:1077.","journal-title":"Front Physiol"},{"key":"1758_CR17","doi-asserted-by":"publisher","first-page":"4161","DOI":"10.1002\/ehf2.13509","volume":"8","author":"K Mozawa","year":"2021","unstructured":"Mozawa K, Kubota Y, Hoshika Y, et al. Empagliflozin confers reno-protection in acute myocardial infarction and type 2 diabetes mellitus. ESC Hear Fail. 2021;8:4161\u201373.","journal-title":"ESC Hear Fail"},{"key":"1758_CR18","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ahj.2019.12.004","volume":"221","author":"NJ Tripolt","year":"2020","unstructured":"Tripolt NJ, Kolesnik E, Pferschy PN, et al. EMMY study group. Impact of EMpagliflozin on cardiac function and biomarkers of heart failure in patients with acute MYocardial infarction\u2014the EMMY trial. Am Heart J. 2020;221:39\u201347.","journal-title":"Am Heart J"},{"key":"1758_CR19","unstructured":"Clinicaltrials.gov. NCT04564742\u2014Dapagliflozin effects on cardiovascular events in patients with an acute heart attack (DAPA-MI). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04564742. Published 2021."},{"key":"1758_CR20","doi-asserted-by":"publisher","first-page":"69","DOI":"10.2337\/dc16-0621","volume":"40","author":"O Mosenzon","year":"2017","unstructured":"Mosenzon O, Leibowitz G, Bhatt DL, et al. Effect of Saxagliptin on renal outcomes in the SAVOR-TIMI 53 Trial. Diabetes Care. 2017;40:69\u201376.","journal-title":"Diabetes Care"},{"key":"1758_CR21","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1001\/jama.2018.18269","volume":"321","author":"J Rosenstock","year":"2019","unstructured":"Rosenstock J, Perkovic V, Johansen OE, et al. CARMELINA investigators effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAM. 2019;321:69\u201379.","journal-title":"JAM"},{"key":"1758_CR22","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1161\/CIRCOUTCOMES.112.965491","volume":"5","author":"MO Gore","year":"2012","unstructured":"Gore MO, Patel MJ, Kosiborod M, et al. National registry of myocardial infarction investigators diabetes mellitus and trends in hospital survival after myocardial infarction, 1994 to 2006. Circ Cardiovasc Qual Outcomes. 2012;5:791\u20137.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"1758_CR23","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1001\/jama.298.7.765","volume":"298","author":"SM Donahoe","year":"2007","unstructured":"Donahoe SM, Stewart GC, McCabe CH, et al. Diabetes and mortality following acute coronary syndromes. JAMA. 2007;298:765.","journal-title":"JAMA"},{"key":"1758_CR24","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1161\/01.CIR.94.8.1818","volume":"94","author":"KE Kip","year":"1996","unstructured":"Kip KE, Faxon DP, Detre KM, Yeh W, Kelsey SF, Currier JW. Coronary angioplasty in diabetic patients. Circulation. 1996;94:1818\u201325.","journal-title":"Circulation"},{"key":"1758_CR25","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s12933-016-0369-6","volume":"15","author":"AO Odegaard","year":"2016","unstructured":"Odegaard AO, Jacobs DR, Sanchez OA, Goff DC, Reiner AP, Gross MD. Oxidative stress, inflammation, endothelial dysfunction and incidence of type 2 diabetes. Cardiovasc Diabetol. 2016;15:51.","journal-title":"Cardiovasc Diabetol"},{"key":"1758_CR26","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","volume":"373","author":"MA Pfeffer","year":"2015","unstructured":"Pfeffer MA, Claggett B, Diaz R, et al. ELIXA investigators lixisenatide in patients with Type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373:2247\u201357.","journal-title":"N Engl J Med"},{"key":"1758_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-020-01127-z","author":"W Shimizu","year":"2020","unstructured":"Shimizu W, Kubota Y, Hoshika Y, et al. EMBODY trial investigators. Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial. Cardiovasc Diabetol. 2020. https:\/\/doi.org\/10.1186\/s12933-020-01127-z.","journal-title":"Cardiovasc Diabetol"},{"key":"1758_CR28","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1093\/ehjcvp\/pvaa004","volume":"7","author":"M Trevisan","year":"2021","unstructured":"Trevisan M, Fu EL, Szummer K, et al. Glucagon-like peptide-1 receptor agonists and the risk of cardiovascular events in diabetes patients surviving an acute myocardial infarction. Eur Heart J Cardiovascular Pharmacother. 2021;7:104\u201311.","journal-title":"Eur Heart J Cardiovascular Pharmacother"},{"key":"1758_CR29","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.jacc.2008.10.033","volume":"53","author":"L Timmers","year":"2009","unstructured":"Timmers L, Henriques JP, de Kleijn DP, et al. Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coll Cardiol. 2009;53:501\u201310.","journal-title":"J Am Coll Cardiol"},{"key":"1758_CR30","doi-asserted-by":"publisher","first-page":"975","DOI":"10.2337\/db08-1193","volume":"58","author":"MH Noyan-Ashraf","year":"2009","unstructured":"Noyan-Ashraf MH, Momen MA, Ban K, et al. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes. 2009;58:975\u201383.","journal-title":"Diabetes"},{"key":"1758_CR31","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s12933-019-0937-7","volume":"18","author":"JR Lundgren","year":"2019","unstructured":"Lundgren JR, F\u00e6rch K, Witte DR, et al. Greater glucagon-like peptide-1 responses to oral glucose are associated with lower central and peripheral blood pressures. Cardiovasc Diabetol. 2019;18:130.","journal-title":"Cardiovasc Diabetol"},{"key":"1758_CR32","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1002\/osp4.133","volume":"3","author":"L Engelbrechtsen","year":"2017","unstructured":"Engelbrechtsen L, Lundgren J, Wewer Albrechtsen NJ, et al. Treatment with liraglutide may improve markers of CVD reflected by reduced levels of apoB. Obes Sci Pract. 2017;3:425\u201333.","journal-title":"Obes Sci Pract"},{"key":"1758_CR33","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1111\/j.1463-1326.2011.01388.x","volume":"13","author":"SS Torekov","year":"2011","unstructured":"Torekov SS, Kipnes MS, Harley RE, Holst JJ, Ehlers MR. Dose response of subcutaneous GLP-1 infusion in patients with type 2 diabetes. Diabetes Obes Metab. 2011;13:639\u201343.","journal-title":"Diabetes Obes Metab"},{"key":"1758_CR34","doi-asserted-by":"publisher","first-page":"e13741","DOI":"10.14814\/phy2.13741","volume":"6","author":"M Mizuno","year":"2018","unstructured":"Mizuno M, Kuno A, Yano T, et al. Empagliflozin normalizes the size and number of mitochondria and prevents reduction in mitochondrial size after myocardial infarction in diabetic hearts. Physiol Rep. 2018;6:e13741.","journal-title":"Physiol Rep"},{"key":"1758_CR35","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1007\/s13238-020-00809-4","volume":"13","author":"K Jiang","year":"2022","unstructured":"Jiang K, Xu Y, Wang D, et al. Cardioprotective mechanism of SGLT2 inhibitor against myocardial infarction is through reduction of autosis. Protein Cell. 2022;13:336\u201359.","journal-title":"Protein Cell"},{"key":"1758_CR36","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-021-07291-y","author":"B Pitt","year":"2022","unstructured":"Pitt B, Steg G, Leiter LA, Bhatt DL. The role of combined SGLT1\/SGLT2 inhibition in reducing the incidence of stroke and myocardial infarction in patients with type 2 diabetes. Cardiovasc Drugs Therapy. 2022. https:\/\/doi.org\/10.1007\/s10557-021-07291-y.","journal-title":"Cardiovasc Drugs Therapy"},{"key":"1758_CR37","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1016\/j.numecd.2021.02.003","volume":"31","author":"N Cosentino","year":"2021","unstructured":"Cosentino N, Bonomi A, Campodonico J, et al. Can the in-hospital mortality gap between STEMI patients with and without diabetes mellitus be reduced? The cardio-renal hypothesis. Nutr Metab Cardiovasc Dis. 2021;31:1516\u201320.","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"1758_CR38","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2020-001451","volume":"8","author":"E Longato","year":"2020","unstructured":"Longato E, Di Camillo B, Sparacino G, Gubian L, Avogaro A, Fadini GP. Cardiovascular outcomes of type 2 diabetic patients treated with SGLT-2 inhibitors versus GLP-1 receptor agonists in real-life. BMJ Open Diabetes Res Care. 2020;8: e001451.","journal-title":"BMJ Open Diabetes Res Care"},{"key":"1758_CR39","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s12933-022-01572-y","volume":"21","author":"M Baviera","year":"2022","unstructured":"Baviera M, Foresta A, Colacioppo P, et al. Effectiveness and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in type 2 diabetes: an Italian cohort study. Cardiovasc Diabetol. 2022;21:162.","journal-title":"Cardiovasc Diabetol"},{"key":"1758_CR40","doi-asserted-by":"publisher","first-page":"826","DOI":"10.2337\/dc20-1464","volume":"44","author":"E Patorno","year":"2021","unstructured":"Patorno E, Pawar A, Bessette LG, et al. Comparative effectiveness and safety of sodium-glucose cotransporter 2 inhibitors versus glucagon-like peptide 1 receptor agonists in older adults. Diabetes Care. 2021;44:826\u201335.","journal-title":"Diabetes Care"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-023-01758-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-023-01758-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-023-01758-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T18:04:33Z","timestamp":1675706673000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-023-01758-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,6]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1758"],"URL":"https:\/\/doi.org\/10.1186\/s12933-023-01758-y","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,6]]},"assertion":[{"value":"11 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"In Italy, studies using retrospective aggregated-anonymous data from administrative databases do not require Ethics Committee approval nor notification. The data underlying this article were provided by the Lombardy region by permission and cannot be shared without permission of the Lombardy region.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"26"}}